ResearcherHôpital BeaujonActive in the last 2 years
Éric François
Matched on ORCID iD 0000-0001-6471-8159; OpenAlex author ID A5052299853. Sources: ClinicalTrials.gov.
Their work
- Papers
- 12 (first author 0, last author 2)
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 58
2008: 1 trial · 2009: none · 2010: none · 2011: none · 2012: 2 papers · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper
Papers 12
- Impact of low muscle mass and myosteatosis on treatment toxicity and survival outcomes in non-resectable pancreatic cancer patients treated with chemoradiother… Co-author DOI 10.1038/s41430-025-01566-5↗
- Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae079↗
- Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CC… Co-author DOI 10.1200/jco.22.02668↗
- Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
- Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. Co-author DOI 10.1038/s41416-021-01341-w↗
- Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. Last author DOI 10.1200/jco.20.03329↗
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1809775↗
- Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach. Co-author DOI 10.1097/ftd.0000000000000399↗
- Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX. Last author DOI 10.1159/000444854↗
- FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Co-author DOI 10.1245/s10434-014-3898-9↗
- BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic … Co-author DOI 10.1093/annonc/mds135↗
- Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. Co-author DOI 10.1159/000343969↗
Trials 1
Closest collaborators
The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jean‐Baptiste Bachet · 5 shared papers, 2015–2024 · strength 0.46
- Paper Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature:… DOI 10.1200/jco.22.02668↗
- Paper Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results o… DOI 10.1200/jco.20.03329↗
- Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
- Olivier Bouché · 2 shared papers, 2021–2025 · strength 0.33
- Paper Impact of low muscle mass and myosteatosis on treatment toxicity and survival outcomes in non-resectable pancreatic can… DOI 10.1038/s41430-025-01566-5↗
- Paper Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results o… DOI 10.1200/jco.20.03329↗
- Anthony Turpin · 2 shared papers, 2021–2024 · strength 0.27
- Paper Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature:… DOI 10.1200/jco.22.02668↗
- Paper Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results o… DOI 10.1200/jco.20.03329↗
- Florian Slimano · 1 shared paper, 2025 · strength 0.22
- Mathias Brügel · 1 shared paper, 2025 · strength 0.22
- Marine Perrier · 1 shared paper, 2025 · strength 0.22
- Thierry Conroy · 2 shared papers, 2018–2024 · strength 0.22
- James Biagi · 2 shared papers, 2018–2024 · strength 0.22
- Pascal R. Hammel · 2 shared papers, 2018–2024 · strength 0.22
- Alice Chia-Chi Wei · 2 shared papers, 2018–2024 · strength 0.22
- Nicolas Williet · 2 shared papers, 2021 · strength 0.20
- Paper Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results o… DOI 10.1200/jco.20.03329↗
- Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
- David Malka · 3 shared papers, 2015–2021 · strength 0.20
- Paper Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results o… DOI 10.1200/jco.20.03329↗
- Paper FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. DOI 10.1056/nejmoa1809775↗
- Paper FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational coh… DOI 10.1245/s10434-014-3898-9↗
- Laëtitia Dahan · 3 shared papers, 2012–2021 · strength 0.19
- Paper Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results o… DOI 10.1200/jco.20.03329↗
- Paper Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampl… DOI 10.1097/ftd.0000000000000399↗
- Paper BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus place… DOI 10.1093/annonc/mds135↗
- Emmanuel Mitry · 1 shared paper, 2024 · strength 0.16
- Rémy Nicolle · 1 shared paper, 2024 · strength 0.16
- Vinciane Rebours · 1 shared paper, 2024 · strength 0.16
- Jerome F. Cros · 1 shared paper, 2024 · strength 0.16
- Aurélien Lambert · 1 shared paper, 2024 · strength 0.16
- Daniel John Renouf · 1 shared paper, 2024 · strength 0.16
- Juan Iovanna · 1 shared paper, 2024 · strength 0.16
- Alexandre Harlé · 1 shared paper, 2024 · strength 0.16
- Nelson Dusetti · 1 shared paper, 2024 · strength 0.16
- Christelle de la Fouchardière · 2 shared papers, 2015–2021 · strength 0.14
- Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
- Paper FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational coh… DOI 10.1245/s10434-014-3898-9↗
- António Sá Cunha · 2 shared papers, 2015–2021 · strength 0.14
- Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
- Paper FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational coh… DOI 10.1245/s10434-014-3898-9↗
- Lysiane Marthey · 2 shared papers, 2015–2021 · strength 0.14
- Paper Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: updat… DOI 10.1038/s41416-021-01341-w↗
- Paper FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational coh… DOI 10.1245/s10434-014-3898-9↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.